USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Trilostane Powder (13647-35-3)

Rating: SKU: 13647-35-3. Category:

AASraw is with synthesis and production ability from gram to mass order of Trilostane Powder (13647-35-3), under CGMP regulation and trackable quality control system.

Product Description

 

Trilostane Powder (13647-35-3) video

 

 


 

Trilostane Powder (13647-35-3) Specification:

Chemical Structure: Product Name: Trilostane
  Cas No.: 13647-35-3
Molecular Formula: C20H27NO3
Molecular Weight: 329.43
Standard: In-house
Storage: Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Documents(COA & HPLC etc.): Available

 

Trilostane Powder (13647-35-3) Description:

Trilostane powder is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing’s syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane powder helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders.

Trilostane powder can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause.

It was recently approved in 2008 for the treatment of Cushing’s disease (hyperandrenocorticism) in dogs. It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing’s in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.

 

Reference:

  •  1: Midence JN, Drobatz KJ, Hess RS. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane. J Vet Intern Med. 2015 Nov;29(6):1529-33. doi: 10.1111/jvim.13615. Epub 2015 Sep 16. PubMed PMID: 26374943.
  • 2: Fracassi F, Corradini S, Floriano D, Boari A, Aste G, Pietra M, Bergamini PF, Dondi F. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Vet Rec. 2015 Jan 10;176(2):49. doi: 10.1136/vr.102546. Epub 2014 Aug 28. PubMed PMID: 25170036.
  • 3: Bonadio CM, Feldman EC, Cohen TA, Kass PH. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism. J Vet Intern Med. 2014 Jul-Aug;28(4):1239-43. doi: 10.1111/jvim.12357. Epub 2014 May 26. PubMed PMID: 24863172.

 

PRECAUTION AND DISCLAIMER:

This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.

 


COA

HNMR

References & product citations